Major US distributor of pharmaceuticals and medical-surgical products to pharmacies, hospitals and labs, plus own-brand medical products.
Major US distributor of pharmaceuticals and medical-surgical products to pharmacies, hospitals and labs, plus own-brand medical products.
Resells branded and generic drugs to pharmacies and hospitals for a thin margin, and earns more from generics through Red Oak Sourcing, a purchasing venture with CVS. A few large pharmacy chains, notably CVS and Walgreens, provide a big share of sales. Its Medical segment sells own-brand gloves, gowns and kits and has been rebuilding margins.
Moat: narrow (scale, distribution). National-scale logistics network across both drug and medical-surgical supply chains.
Headquarters: Dublin, Ohio, USA · Founded: 1971 · Employees: 63,900
Size Cardinal Health (CAH) is a United States Health Care company (Medical Distributors) with a market value of $64.3B, the 205th largest of 3,085 United States companies the cockpit tracks. Shares closed at $278.32 on 18 Nov 2026.
Performance Over six months the shares gained 40.0%, against +11.7% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 10.0% over the last twelve months (peer median +6.2%); the operating margin is 1.3% (peer median 2.9%).
Valuation It trades at 21.1× forward earnings against a peer median of 17.0× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -2 pp: the price already allows for a slowdown.
Credit Cardinal Health has 13 bonds outstanding ($7.98B), rated BBB by the agencies and trading like A- at a weighted spread of 91 bp.
Short interest Short interest is 3.3% of the free float (30 Oct 2026).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $258B | $254B | $223B | $227B | $205B |
| Revenue growth | — | +14% | -2% | +11% | — |
| Gross profit | $9.68B | $9.40B | $7.86B | $7.15B | $6.59B |
| EBITDA | $4.38B | $4.22B | $3.26B | $2.86B | $2.48B |
| Net income | $1.82B | $1.71B | $1.56B | $852M | $330M |
| Free cash flow | $4.90B | $4.53B | $1.85B | $3.25B | $2.36B |
| Capital expenditure | $698M | $649M | $547M | $511M | $481M |
| Total debt | $8.81B | $9.95B | $9.35B | $5.61B | $5.18B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cardinal Health CAH | $64.3B | +40% | +10% | 1% | 21.1× | 7.8% |
| McKesson MCK | $125B | +44% | +8% | 2% | 22.1× | -5.5% |
| Cencora COR | $66.5B | +32% | +5% | 1% | 17.7× | -1.2% |
| Medline MDLN | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CAH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.1% | +1.8% | 4th highest of 21 |
| 6-month return | +40.0% | +11.7% | 5th highest of 21 |
| Distance from 52-week high | -2.8% | -13.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +10.0% | +6.2% | 4th highest of 21 |
| Operating margin | 1.3% | 2.9% | 6th lowest of 21 |
| Forward P/E | 21.1× | 17.0× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 7.8% | -1.2% | 3rd most demanding of 18 |
| Growth delivered (Del g) | +9.4% | +5.4% | 6th highest of 18 |
| Hurdle (Req g minus delivered) | -1.5 pp | -8.1 pp | 4th most demanding of 18 |
| Net debt / EBITDA | 0.8× | 0.6× | 9th most indebted of 18 |
| Bond spread | 91 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cardinal Health CAH | United States | $64.3B | +40% | +10% | 1% | 21.1× | 7.8% | +9.4% |
| Cencora COR | United States | $66.5B | +32% | +5% | 1% | 17.7× | -1.2% | +9.5% |
| McKesson MCK | United States | $125B | +44% | +8% | 2% | 22.1× | -5.5% | +11.1% |
| Henry Schein HSIC | United States | $9.47B | +17% | +6% | 6% | 14.7× | 10.2% | +5.4% |
| Sinopharm 1099.HK | Hong Kong | $6.74B | 0% | +3% | 3% | 6.2× | -7.3% | +4.0% |
| DKSH DKSH.SW | Switzerland | $5.99B | +24% | -1% | 3% | 21.8× | -1.2% | +0.6% |
| Galenica GALE.SW | Switzerland | $5.31B | +8% | +6% | 5% | 23.9× | 7.0% | +3.5% |
| Jointown Pharmaceutical 600998.SS | China | $3.99B | +7% | +9% | 2% | 11.8× | 0.2% | +7.8% |
| MEDIPAL 7459.T | Japan | $3.70B | +15% | +4% | 1% | 12.5× | -7.2% | +3.5% |
| Amplifon AMP.MI | Italy | $3.39B | +8% | 0% | 10% | 17.0× | 6.8% | +9.8% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.21B | +2% | +9% | 4% | 15.9× | n/a | n/a |
| Alfresa 2784.T | Japan | $2.81B | -3% | +4% | 1% | 18.4× | -8.4% | +3.5% |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 24.8× | 4.7% | +12.7% |
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | n/a | 26.0% | +9.6% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 15.8× | -10.4% | +3.2% |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 22.2× | -4.6% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | n/a | n/a | n/a |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% | +7.6% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% | +1.2% |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
Cardinal Health has 13 bonds outstanding with $7.98B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 5.83%, a spread of 91 bp over government bonds.